Vision-Sciences Inc (VSCI) Reports Q1 Loss of $0.04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vision-Sciences Reports First Quarter Fiscal 2015 Results
August 4, 2014 4:30 PM EDTORANGEBURG, N.Y., Aug. 4, 2014 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq: VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath® technology, today announced financial results for the first quarter of fiscal 2015, ended June 30, 2014.
First Quarter Fiscal Year 2015 Highlights
Net sales increased 3% to $3.8 million as compared with $3.7 million in first quarter of fiscal 2014; Operating loss improved 21% to $(1.9) million; Net loss improved by 19% to $(2.0) million, or ($0.04) per basic and diluted share; and Vision-Sciences chose not to renew an agreement with Stryker Corporation for the... More